Background: Diabetes mellitus is a metabolic disorder that affects the heart, brain, eye, and other organs. Diabetic microvascular complications includes retinopathy, nephropathy, and neuropathy. Diabetic retinopathy is a multifactorial disease that develops as a consequence of microvascular
complications, which causes damage to the retina by damaging the ocular fundus which further leads to visual loss.
Purpose: Pharmacological and non-pharmacological treatment works to prevent, delay or reduce vision loss. Non-pharmacological treatment include nutraceuticals (they have anti-inflammatory and antioxidant property) and pharmacological treatment includes anti-VEGF agents, corticosteroids, and specific moieties. Treatment with nutraceuticals in the early stages of diabetic retinopathy could be a viable option for intervening before the disease progresses.
Conclusion: This review briefly elucidates the emerging condition of diabetic retinopathy from epidemiological, pathophysiological, and therapeutic aspects including the emerging uses of nutraceuticals in diabetic retinopathy. If we control glucose and blood pressure levels in diabetic patients, it may halt the progression and development of diabetic retinopathy.
Ahmadinejad, F., Geir Møller, S., Hashemzadeh-Chaleshtori, M., Bidkhori, G., & Jami, M. S. (2017). Molecular Mechanisms behind Free Radical Scavengers Function against Oxidative Stress. Antioxidants (Basel, Switzerland), 6(3), 51. https://doi.org/10.3390/antiox6030051
Aiello, L. P., Edwards, A. R., Beck, R. W., Bressler, N. M., Davis, M. D., Ferris, F., Glassman, A. R., Ip, M. S., Miller, K. M., & Diabetic Retinopathy Clinical Research Network (2010). Factors associated with improvement and worsening of visual acuity 2 years after focal/grid photocoagulation for diabetic macular edema. Ophthalmology, 117(5), 946–953. https://doi.org/10.1016/j.ophtha.2009.10.002
Alberti, K. G., & Zimmet, P. Z. (1998). Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabetic Medicine: A Journal of the British Diabetic Association, 15(7), 539–553. https://doi.org/10.1002/(SICI)1096-9136(199807)15:7<539::AID-DIA668>3.0.CO;2-S
Amato, R., Rossino, M. G., Cammalleri, M., Locri, F., Pucci, L., Dal Monte, M., & Casini, G. (2018). Lisosan G Protects the Retina from Neurovascular Damage in Experimental Diabetic Retinopathy. Nutrients, 10(12), 1932. https://doi.org/10.3390/nu10121932.
American Diabetes Association (2013). Diagnosis and classification of diabetes mellitus. Diabetes Care, 36 Suppl 1(Suppl 1), S67–S74. https://doi.org/10.2337/dc13-S067
Andreasson, R., Ekelund, C., Landin-Olsson, M., & Nilsson, C. (2018). HbA1c levels in children with type 1 diabetes and correlation to diabetic retinopathy. Journal of Pediatric Endocrinology & Metabolism: JPEM, 31(4), 369–374. https://doi.org/10.1515/jpem-2017-0417
Bandello, F., Battaglia Parodi, M., Lanzetta, P., Loewenstein, A., Massin, P., Menchini, F., & Veritti, D. (2010). Diabetic macular edema. Developments in Ophthalmology, 47, 73–110. https://doi.org/10.1159/00032007573-110
Boyer, D. S., Yoon, Y. H., Belfort, R., Jr, Bandello, F., Maturi, R. K., Augustin, A. J., Li, X. Y., Cui, H., Hashad, Y., Whitcup, S. M., & Ozurdex MEAD Study Group (2014). Three-year, randomized, sham-controlled trial of dexamethasone intravitreal implant in patients with diabetic macular edema. Ophthalmology, 121(10), 1904–1914. https://doi.org/10.1016/j.ophtha.2014.04.024
Brown, M. M., Brown, G. C., Sharma, S., Landy, J., & Bakal, J. (2002). Quality of life with visual acuity loss from diabetic retinopathy and age-related macular degeneration. Archives of Ophthalmology (Chicago, Ill. : 1960), 120(4), 481–484. https://doi.org/10.1001/archopht.120.4.481
Campochiaro, P. A., Brown, D. M., Pearson, A., Chen, S., Boyer, D., Ruiz-Moreno, J., Garretson, B., Gupta, A., Hariprasad, S. M., Bailey, C., Reichel, E., Soubrane, G., Kapik, B., Billman, K., Kane, F. E., Green, K., & FAME Study Group (2012). Sustained delivery fluocinolone acetonide vitreous inserts provide benefit for at least 3 years in patients with diabetic macular edema. Ophthalmology, 119(10), 2125–2132. https://doi.org/10.1016/j.ophtha.2012.04.030
Cao, H., Ou, J., Chen, L., Zhang, Y., Szkudelski, T., Delmas, D., Daglia, M., & Xiao, J. (2019). Dietary polyphenols and type 2 diabetes: Human Study and Clinical Trial. Critical Reviews in Food Science and Nutrition, 59(20), 3371–3379.https://doi.org/10.1080/10408398.2018.1492900
Chawla, A., Chawla, R., & Jaggi, S. (2016). Microvasular and macrovascular complications in diabetes mellitus: Distinct or continuum? Indian Journal of Endocrinology and Metabolism, 20(4), 546–551. https://doi.org/10.4103/2230-8210.183480
Cheung, N., Mitchell, P., & Wong, T. Y. (2010). Diabetic retinopathy. Lancet (London, England), 376(9735), 124–136. https://doi.org/10.1016/S0140-6736(09)62124-3
Cohen, S. R., & Gardner, T. W. (2016). Diabetic Retinopathy and Diabetic Macular Edema. Developments in Ophthalmology, 55, 137–146. https://doi.org/10.1159/000438970
Borodina, T., Kostyushev, D., Zamyatnin, A. A., & Parodi, A. (2021). Nanomedicine for Treating Diabetic Retinopathy Vascular Degeneration. International Journal of Translational Medicine, 1(3), 306-322
Deswal, J., Narang, S., Gupta, N., Jinagal, J., & Sindhu, M. (2020). To study the impact of diabetic retinopathy on quality of life in Indian diabetic patients. Indian Journal of Ophthalmology, 68(5), 848–853. https://doi.org/10.4103/ijo.IJO_1553_19
Dong, C., Liu, P., Wang, H., Dong, M., Li, G., & Li, Y. (2019). Ginsenoside Rb1 attenuates diabetic retinopathy in streptozotocin-induced diabetic rats1. Acta Cirurgica Brasileira, 34(2), e201900201. https://doi.org/10.1590/s0102-8650201900201
Effects of aspirin treatment on diabetic retinopathy. ETDRS report number 8. Early Treatment Diabetic Retinopathy Study Research Group. (1991). Ophthalmology, 98(5 Suppl), 757–765
Fathalipour, M., Fathalipour, H., Safa, O., Nowrouzi-Sohrabi, P., Mirkhani, H., & Hassanipour, S. (2020). The Therapeutic Role of Carotenoids in Diabetic Retinopathy: A Systematic Review. Diabetes, Metabolics Syndrome and Obesity Targets and Therapy, 13, 2347–2358. https://doi.org/10.2147/DMSO.S255783.
Gao, Y., Ji, Y., Luo, Y., Sun, J., Sun, G., & Sun, X. (2020). Ginsenoside Rg1 prevents early diabetic retinopathy via reducing retinal ganglion cell layer and inner nuclear layer cell apoptosis in db/db mice. Annals of Translational Medicine, 8(5), 232. https://doi.org/10.21037/atm.2019.12.155
Hendrick, A. M., Gibson, M. V., & Kulshreshtha, A. (2015). Diabetic Retinopathy. Primary Care, 42(3), 451–464. https://doi.org/10.1016/j.pop.2015.05.005
Heng, L. Z., Comyn, O., Peto, T., Tadros, C., Ng, E., Sivaprasad, S., & Hykin, P. G. (2013). Diabetic retinopathy: pathogenesis, clinical grading, management and future developments. Diabetic Medicine: A Journal of the British Diabetic Association, 30(6), 640–650. https://doi.org/10.1111/dme.12089
https://www.clinicaltrials.gov
Kaštelan, S., Tomić, M., Gverović Antunica, A., Salopek Rabatić, J., & Ljubić, S. (2013). Inflammation and pharmacological treatment in diabetic retinopathy. Mediators of inflammation, 2013, 213130. https://doi.org/10.1155/2013/213130
Kim, S. J., Flach, A. J., & Jampol, L. M. (2010). Nonsteroidal anti-inflammatory drugs in ophthalmology. Survey of Opthalmology, 55(2), 108–133. https://doi.org/10.1016/j.survophthal.2009.07.005
Klein, B. E., Moss, S. E., & Klein, R. (1990). Effect of pregnancy on progression of diabetic retinopathy. Diabetes Care, 13(1), 34–40. https://doi.org/10.2337/diacare.13.1.34
Kwan, C. C., & Fawzi, A. A. (2019). Imaging and Biomarkers in Diabetic Macular Edema and Diabetic Retinopathy. Current diabetes reports, 19(10), 95. https://doi.org/10.1007/s11892-019-1226-2
Lightman, S., & Towler, H. M. (2003). Diabetic retinopathy. Clinical Cornerstone, 5(2), 12–21. https://doi.org/10.1016/s1098-3597(03)90015-9
Morrison, J. L., Hodgson, L. A., Lim, L. L., & Al-Qureshi, S. (2016). Diabetic retinopathy in pregnancy: a review. Clinical &Experimental Ophthalmology, 44(4), 321–334. https://doi.org/10.1111/ceo.12760
Nabavi, S. F., Barber, A. J., Spagnuolo, C., Russo, G. L., Daglia, M., Nabavi, S. M., & Sobarzo-Sánchez, E. (2016). Nrf2 as molecular target for polyphenols: A novel therapeutic strategy in diabetic retinopathy. Critical Reviews in Clinical Laboratory Sciences, 53(5), 293–312. https://doi.org/10.3109/10408363.2015.1129530
Nimse, S. B., & Pal, D. (2015). Free radicals, natural antioxidants, and their reaction mechanisms. RSC Advances, 5(35), 27986-28006
Pereira, D. M., Shah, A., D’Souza, M., Simon, P., George, T., D’Souza, N., Suresh, S., & Baliga, M. S. (2017). Quality of Life in People with Diabetic Retinopathy: Indian Study. Journal of Clinical and Diagnostic Research: JCDR, 11(4), NC01–NC06. https://doi.org/10.7860/JCDR/2017/24496.9686
Porta, M., & Bandello, F. (2002). Diabetic retinopathyA clinical update. Diabetologia, 45(12), 1617–1634. https://doi.org/10.1007/s00125-002-0990-7
Rossino, M. G., & Casini, G. (2019). Nutraceuticals for the Treatment of Diabetic Retinopathy. Nutrients, 11(4), 771. https://doi.org/10.3390/nu11040771
Sahoo, S., Barua, A., Myint, K. T., Haq, A., Abas, A. B., & Nair, N. S. (2015). Topical non-steroidal anti-inflammatory agents for diabetic cystoid macular oedema. The Cochrane Database of Systematic Reviews, (2), CD010009. https://doi.org/10.1002/14651858.CD010009.pub2
Sak, D., Erdenen, F., Müderrisoglu, C., Altunoglu, E., Sozer, V., Gungel, H., Guler, P. A., Sak, T., & Uzun, H. (2019). The Relationship between Plasma Taurine Levels and Diabetic Complications in Patients with Type 2 Diabetes Mellitus. Biomolecules, 9(3), 96. https://doi.org/10.3390/biom9030096
Garg, S., & Davis, R. M. (2009). Diabetic retinopathy screening update. Clinical Diabetes, 27(4), 140-145. https://doi.org/10.2337/diaclin.27.4.140
Semeraro, F., Russo, A., Gambicorti, E., Duse, S., Morescalchi, F., Vezzoli, S., & Costagliola, C. (2015). Efficacy and vitreous levels of topical NSAIDs. Expert Opinion on Drug Delivery, 12(11), 1767–1782. https://doi.org/10.1517/17425247.2015.1068756
Sun, H. H., Chai, X. L., Li, H. L., Tian, J. Y., Jiang, K. X., Song, X. Z., Wang, X. R., Fang, Y. S., Ji, Q., Liu, H., Hao, G. M., Wang, W., & Han, J. (2021). Fufang Xueshuantong alleviates diabetic retinopathy by activating the PPAR signalling pathway and complement and coagulation cascades. Journal of Ethnopharmacology, 265, 113324. https://doi.org/10.1016/j.jep.2020.113324
Tan, C. S., Chew, M. C., Lim, L. W., & Sadda, S. R. (2016). Advances in retinal imaging for diabetic retinopathy and diabetic macular edema. Indian Journal of Ophthalmology, 64(1), 76–83. https://doi.org/10.4103/0301-4738.178145
UK Prospective Diabetes Study Group (1998). Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group. BMJ (Clinical research ed.), 317(7160), 703–713
Unnikrishnan, R., Anjana, R. M., & Mohan, V. (2016). Diabetes mellitus and its complications in India. Nature reviews. Endocrinology, 12(6), 357–370. https://doi.org/10.1038/nrendo.2016.53
Diabetic Retinopathy Clinical Research Network, Wells, J. A., Glassman, A. R., Ayala, A. R., Jampol, L. M., Aiello, L. P., Antoszyk, A. N., Arnold-Bush, B., Baker, C. W., Bressler, N. M., Browning, D. J., Elman, M. J., Ferris, F. L., Friedman, S. M., Melia, M., Pieramici, D. J., Sun, J. K., & Beck, R. W. (2015). Aflibercept, bevacizumab, or ranibizumab for diabetic macular edema. The New England Journal of Medicine, 372(13), 1193–1203. https://doi.org/10.1056/NEJMoa1414264
Wells, J. A., Glassman, A. R., Ayala, A. R., Jampol, L. M., Bressler, N. M., Bressler, S. B., Brucker, A. J., Ferris, F. L., Hampton, G. R., Jhaveri, C., Melia, M., Beck, R. W., & Diabetic Retinopathy Clinical Research Network (2016). Aflibercept, Bevacizumab, or Ranibizumab for Diabetic Macular Edema: Two-Year Results from a Comparative Effectiveness Randomized Clinical Trial. Ophthalmology, 123(6), 1351–1359. https://doi.org/10.1016/j.ophtha.2016.02.022
Whitehead, M., Wickremasinghe, S., Osborne, A., Van Wijngaarden, P., & Martin, K. R. (2018). Diabetic retinopathy: a complex pathophysiology requiring novel therapeutic strategies. Expert Opinion on Biological Therapy, 18(12), 1257-1270. https://doi.org/10.1080/14712598.2018.1545836
Woodcock, A., Bradley, C., Plowright, R., ffytche, T., Kennedy-Martin, T., & Hirsch, A. (2004). The influence of diabetic retinopathy on quality of life: interviews to guide the design of a condition-specific, individualised questionnaire: the RetDQoL. Patient Education and Counseling, 53(3), 365–383. https://doi.org/10.1016/j.pec.2003.10.007
Writing Team for the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group (2002). Effect of intensive therapy on the microvascular complications of type 1 diabetes mellitus. JAMA, 287(19), 2563–2569. https://doi.org/10.1001/jama.287.19.2563
Yau, J. W., Rogers, S. L., Kawasaki, R., Lamoureux, E. L., Kowalski, J. W., Bek, T., Chen, S. J., Dekker, J. M., Fletcher, A., Grauslund, J., Haffner, S., Hamman, R. F., Ikram, M. K., Kayama, T., Klein, B. E., Klein, R., Krishnaiah, S., Mayurasakorn, K., O’Hare, J. P., Orchard, T. J., … Meta-Analysis for Eye Disease (META-EYE) Study Group (2012). Global prevalence and major risk factors of diabetic retinopathy. Diabetes Care, 35(3), 556–564. https://doi.org/10.2337/dc11-1909
Zhou, P., Xie, W., Meng, X., Zhai, Y., Dong, X., Zhang, X., Sun, G., & Sun, X. (2019). Notoginsenoside R1 Ameliorates Diabetic Retinopathy through PINK1-Dependent Activation of Mitophagy. Cells, 8(3), 213. https://doi.org/10.3390/cells8030213
| Periodicity | Biannually |
| Issue-1 | May |
| Issue-2 | November |
| ISSN Print | 2321-2217 |
| ISSN Online | 2321-2225 |
| RNI No. | CHAENG/2013/50088 |
Publisher's policy of the journal at Sherpa UK for the submitted, accepted, and published articles. Click OAPolicy
Plan-S ComplianceTo check compliance, one has to use the Journal Check Tool (JCT). This tool provided by cOAlition S (European funders) for the researchers (fundee) to check the compliance with the journal.
Recommend journal to your libraryYou can recommend the journal being a researcher or faculty member to your library. We will post a copy of the Journal to your library on your behalf at free of cost.
Click here: Recommend Journal
The authors are encouraged to submit the author’s copy (preprint) to appropriate preprint archives e.g. https://arxiv.org and/or on https://indiarxiv.org or institutional repositories (e.g., D Space) before paper acceptance by the editor of Journal. After publications of the paper author(s) should mention the citation information, title and abstract along with DOI number of the publication carefully on the required page of the depository(ies).
Contact: Phone: +91-172-2741000, +91-172-4691800
Email : editor.jptrm@chitkara.edu.in;
This work is licensed under a Creative Commons Attribution 4.0 International License.
View Legal Code of the above-mentioned license, https://creativecommons.org/licenses/by/4.0/legalcode
View Licence Deed here https://creativecommons.org/licenses/by/4.0/
Journal of Pharmaceutical Technology, Research and Management by Chitkara University Publications is licensed under a Creative Commons Attribution 4.0 International License.
Based on a work at https://jptrm.chitkara.edu.in//
Chandigarh-Patiala National Highway, Punjab 140 401
Chandigarh Information Center SCO 160-161, Sector 9-C, Chandigarh 160 009
